CIViC Evidence Items
219 evidence items indexed
Evidence Level Distribution
CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).
AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale
Gene × Evidence Type
Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.
| Predictive | Diagnostic | Prognostic | Functional | Predispos. | Oncogenic | |
|---|---|---|---|---|---|---|
| BCR::ABL1 | 323 | 11 | ||||
| BRAF | 186 | 4 | 26 | 2 | 1 | |
| EGFR | 248 | 12 | 3 | 2 | ||
| EML4::ALK | 64 | |||||
| ERBB2 | 142 | 2 | ||||
| FLT3 | 55 | 2 | 21 | |||
| KIT | 102 | 3 | 7 | |||
| KRAS | 159 | 4 | 24 | 4 | ||
| PIK3CA | 156 | 16 | 4 | |||
| PTEN | 53 | 1 | 3 | 1 | 2 | 1 |
| TP53 | 52 | 40 | 100 | 2 | ||
| VHL | 5 | 2 | 3 | 635 | 15 |
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
| Level | Gene | Variant | Type | Direction | Significance | Disease | Drugs | Source |
|---|---|---|---|---|---|---|---|---|
| C | BRAF | N581S | Predictive | Does Not Support | Sensitivity/Response | Cancer | Vemurafenib | Hainsworth et al., 2018 |
| C | BRAF | G466V | Predictive | Does Not Support | Sensitivity/Response | Cancer | Vemurafenib | Hainsworth et al., 2018 |
| C | BRAF | G596R | Predictive | Does Not Support | Sensitivity/Response | Cancer | Vemurafenib | Hainsworth et al., 2018 |
| C | BRAF | G606E | Predictive | Does Not Support | Sensitivity/Response | Cancer | Vemurafenib | Hainsworth et al., 2018 |
| C | BRAF | L597Q | Predictive | Does Not Support | Sensitivity/Response | Cancer | Vemurafenib | Hainsworth et al., 2018 |
| C | BRAF | P731T | Predictive | Does Not Support | Sensitivity/Response | Cancer | Vemurafenib | Hainsworth et al., 2018 |
| C | BRAF | intron 9 rearrangement | Predictive | Does Not Support | Sensitivity/Response | Cancer | Vemurafenib | Hainsworth et al., 2018 |
| C | BRAF | intron 10 rearrangement | Predictive | Does Not Support | Sensitivity/Response | Cancer | Vemurafenib | Hainsworth et al., 2018 |
| B | BRAF | Amplification AND ( BRAF V600E OR BRAF V600K ) | Predictive | Supports | Resistance | Melanoma | Vemurafenib,Dabrafenib | Shi et al., 2014 |
| D | BRAF | V600E AND PIK3CA Overexpression | Predictive | Supports | Resistance | Melanoma | Vemurafenib | Shi et al., 2014 |
| D | BRAF | A728V | Functional | Supports | Gain of Function | Wan et al., 2004 | ||
| C | BRAF | V600 | Predictive | Supports | Sensitivity/Response | Histiocytic Sarcoma | Dabrafenib/Trametinib Regimen | Tan et al., 2025 |
| C | BRAF | V600E AND BRAF V600M | Predictive | Supports | Sensitivity/Response | Melanoma | Dabrafenib | Ponti et al., 2012 |
| B | BRAF | D594G | Prognostic | Supports | Poor Outcome | Colorectal Cancer | Amaki-Takao et al., 2016 | |
| C | BRAF | D594G | Predictive | Does Not Support | Resistance | Colorectal Cancer | Cetuximab,Panitumumab | Amaki-Takao et al., 2016 |
| C | BRAF | V600E AND ARAF S490T | Predictive | Supports | Resistance | Colorectal Cancer | Cetuximab,Vemurafenib,Irinotecan | Hong et al., 2016 |
| C | BRAF | Exon 15 Mutation | Predictive | Supports | Resistance | Gastrointestinal Stromal Tumor | Regorafenib Anhydrous | George et al., 2012 |
| D | BRAF | G596R | Predictive | Does Not Support | Sensitivity/Response | Colorectal Cancer | Vemurafenib | Yang et al., 2012 |
| B | BRAF | V600K | Predictive | Supports | Sensitivity/Response | Melanoma | Dabrafenib | Long et al., 2011 |
Page 5 of 5